Publication: Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of her2 positive breast cancer patients: A multicenter real-life her2path study
dc.contributor.author | Bilici, Ahmet | |
dc.contributor.author | Ölmez, Ömer Fatih | |
dc.contributor.author | Kaplan, Muhammed Ali | |
dc.contributor.author | Öksüzoğlu, Berna | |
dc.contributor.author | Sezer, Ahmet | |
dc.contributor.author | Karadurmuş, Nuri | |
dc.contributor.author | Sendur, Mehmet Ali Nahit | |
dc.contributor.author | Aksoy, Sercan | |
dc.contributor.author | Erdem, Dilek | |
dc.contributor.author | Başaran, Gül | |
dc.contributor.author | Çakar, Burcu | |
dc.contributor.author | Shbair, Abdallah T. M. | |
dc.contributor.author | Arslan, Çağatay | |
dc.contributor.author | Sümbül, Ahmet Taner | |
dc.contributor.author | Sezgin Göksu, Sema | |
dc.contributor.author | Karadağ, Ibrahim | |
dc.contributor.author | Cicin, Irfan | |
dc.contributor.author | Gümüş, Mahmut | |
dc.contributor.author | Selçukbiricik, Fatih | |
dc.contributor.author | Harputluoglu, Hakan | |
dc.contributor.author | Demirci, Umut | |
dc.contributor.buuauthor | Çubukçu, Erdem | |
dc.contributor.buuauthor | ÇUBUKÇU, ERDEM | |
dc.contributor.department | Tıp Fakültesi | |
dc.contributor.department | İç Hastalıkları Ana Bilim Dalı | |
dc.contributor.researcherid | ETP-1691-2022 | |
dc.date.accessioned | 2024-12-04T05:30:12Z | |
dc.date.available | 2024-12-04T05:30:12Z | |
dc.date.issued | 2023-04-20 | |
dc.description.abstract | AimTo investigate the pathological complete response (pCR) achieved after neoadjuvant therapy with versus without adding pertuzumab (P) to trastuzumab (H) plus neoadjuvant chemotherapy (NCT) in HER2+ breast cancer (BC) patients in a real-life setting.MethodsA total of 1528 female HER2+ BC patients who received NCT plus H with or without P were included in this retrospective real-life study. Primary endpoint was pCR rate (ypT0/Tis ypN0). Clinicopathological characteristics, event-free survival (EFS) time, and relapse rates were evaluated with respect to HER2 blockade (NCT-H vs. NCT-HP) and pCR.ResultsOverall, 62.2% of patients received NCT-H and 37.8% received NCT-HP. NCT-HP was associated with a significantly higher pCR rate (66.4 vs. 56.8%, p < 0.001) and lower relapse (4.5 vs. 12.2%, p < 0.001) in comparison to NCT-H. Patients with pCR had a significantly lower relapse (5.6 vs. 14.9%, p < 0.001) and longer EFS time (mean(SE) 111.2(1.9) vs. 93.9(2.7) months, p < 0.001) compared to patients with non-pCR. Patients in the NCT-HP group were more likely to receive docetaxel (75.0 vs. 40.6%, p < 0.001), while those with pCR were more likely to receive paclitaxel (50.2 vs. 40.7%, p < 0.001) and NCT-HP (41.5 vs. 32.1%, p < 0.001). Hormone receptor status and breast conservation rates were similar in NCT-HP vs. NCT-H groups and in patients with vs. without pCR. Invasive ductal carcinoma (OR, 2.669, 95% CI 1.596 to 4.464, p < 0.001), lower histological grade of the tumor (OR, 4.052, 95% CI 2.446 to 6.713, p < 0.001 for grade 2 and OR, 3.496, 95% CI 2.020 to 6.053, p < 0.001 for grade 3), lower T stage (OR, 1.959, 95% CI 1.411 to 2.720, p < 0.001) and paclitaxel (vs. docetaxel, OR, 1.571, 95% CI 1.127 to 2.190, p = 0.008) significantly predicted the pCR.ConclusionsThis real-life study indicates that adding P to NCT-H enables higher pCR than NCT-H in HER2+ BC, while pCR was associated with lower relapse and better EFS time. | |
dc.identifier.doi | 10.1080/0284186X.2023.2202330 | |
dc.identifier.endpage | 390 | |
dc.identifier.issn | 0284-186X | |
dc.identifier.issue | 4 | |
dc.identifier.startpage | 381 | |
dc.identifier.uri | https://doi.org/10.1080/0284186X.2023.2202330 | |
dc.identifier.uri | https://hdl.handle.net/11452/48845 | |
dc.identifier.volume | 62 | |
dc.identifier.wos | 000971681800001 | |
dc.indexed.wos | WOS.SCI | |
dc.language.iso | en | |
dc.publisher | Taylor & Francis Ltd | |
dc.relation.journal | Acta Oncologica | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Pathological complete response | |
dc.subject | Controlled superiority trial | |
dc.subject | Adjuvant trastuzumab | |
dc.subject | Cardiac safety | |
dc.subject | Open-label | |
dc.subject | Neosphere | |
dc.subject | Regimens | |
dc.subject | Efficacy | |
dc.subject | Her2 protein positive | |
dc.subject | Breast cancer | |
dc.subject | Neoadjuvant treatment | |
dc.subject | Pertuzumab | |
dc.subject | Trastuzumab | |
dc.subject | Event-free survival | |
dc.subject | Relapse | |
dc.subject | Real-word evidence | |
dc.subject | Science & technology | |
dc.subject | Life sciences & biomedicine | |
dc.subject | Oncology | |
dc.title | Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of her2 positive breast cancer patients: A multicenter real-life her2path study | |
dc.type | Article | |
dspace.entity.type | Publication | |
local.contributor.department | Tıp Fakültesi/İç Hastalıkları Ana Bilim Dalı | |
relation.isAuthorOfPublication | f971677f-09c5-4463-bf01-3c6341fbe5f7 | |
relation.isAuthorOfPublication.latestForDiscovery | f971677f-09c5-4463-bf01-3c6341fbe5f7 |